Effect of Dementia on the Use of Drugs for Secondary Prevention of Ischemic Heart Disease
Table 3
Association between dementia and use of one or more classes of guideline-recommended medications for secondary prevention of ischemic heart disease by study participants, 1989 to 1998.
Variable
Odds ratio (95% confidence interval)
Use of an ACE inhibitor
Use of a beta-blocker
Use of a lipid-lowering medication*
Use of an antiplatelet medication†
Use of two or more classes of guideline-recommended medications
Dementia
1.19 (0.79–1.77)
0.97 (0.65–1.44)
0.76 (0.37–1.55)
0.74 (0.45–1.23)
0.60 (0.35–0.99)‡
Age
0.99 (0.94–1.03)
0.98 (0.94–1.02)
0.99 (0.93–1.05)
0.97 (0.94–0.99)‡
0.97 (0.92–0.99)‡
Age and dementia interaction
1.01 (0.92–1.10)
1.03 (0.98–1.07)
0.99 (0.92–1.07)
1.06 (0.99–1.14)
1.10 (1.03–1.19)‡
White race
1.93 (0.95–3.91)
0.91 (0.43–1.92)
2.28 (0.99–5.20)‡
2.66 (1.65–4.30)‡
2.26 (1.34–3.86)‡
Male sex
1.12 (0.69–1.82)
1.32 (0.78–2.23)
1.21 (0.58–2.54)
1.40 (1.00–1.94)
1.24 (0.80–1.90)
Atrial fibrillation
1.16 (0.71–1.90)
0.95 (0.53–1.70)
0.29 (0.15–0.56)‡
0.98 (0.70–1.38)
1.03 (0.66–1.61)
CHF
2.87 (1.33–6.55) ‡
0.40 (0.11–1.28)
1.42 (0.37–5.50)
0.95 (0.49–1.84)
1.12 (0.50–2.53)
Hypertension
1.12 (1.00–1.23)
1.15 (1.08–1.24)‡
1.47 (1.00–2.15)‡
1.07 (0.96–1.19)
1.16 (1.05–1.30)‡
Diabetes
1.21 (1.00–1.46) ‡
0.86 (0.78–0.96)‡
1.14 (0.96–1.37)
1.06 (0.91–1.23)
1.08 (0.94–1.23)
ACE: angiotensin-converting enzyme; CHF: congestive heart failure.
*Lipid-lowering medications included statins (3-hydroxy-3-methyglutaryl-coenzyme A [HMG-CoA] reductase inhibitors) and nonstatins. The model for these medications was restricted to data from 1992 to 1998. †Antiplatelet medications included cyclooxygenase inhibitors (e.g., aspirin) and adenosine diphosphate (ADP) receptor inhibitors. .
